Work

A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantation

Year: 2025

Type: article

Abstract: The advent of direct-acting antiviral agents (DAA) allows for the utilization of hepatitis C (HCV) viremic donors to uninfected recipients. Sofosbuvir/velpatasvir (SOF/VEL) is a pangenotypic DAA without clinically significant interactions with immunosuppressants, but its concomitant use with amiodarone may cause serious bradycardia. In an open-label study of 20 heart and lung transplant recipients of organs from HCV viremic donors, who received SOF/VEL for 12 weeks starting on post-operative day one, the concomitant use of amiodarone and SOF/VEL resulted in bradycardic episodes and commonly occurred in the presence of beta-blocking medications. Episodes of bradycardia were transient, resolved with intervention, and did not require the discontinuation of SOF/VEL. In patients requiring the combination of SOF/VEL and amiodarone, consideration of therapeutic options is warranted prior to the addition of other bradycardia-inducing medications.

Source: JHLT Open

DOI: 10.1016/j.jhlto.2025.100279

Authors: Ryan M. Rivosecchi, Pablo G. Sanchez, Lauren M. Sacha, Edward T. Horn, Mary Keebler, Fernanda P. Silveira

Institutions: UPMC Presbyterian, University of Pittsburgh Medical Center, UPMC Health System, University of Pittsburgh

Language: English

Topic: Hepatitis C virus research

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,500